The stock of AbCellera Biologics Inc (NASDAQ: ABCL) has increased by 0.99 when compared to last closing price of 2.02.Despite this, the company has seen a loss of -2.86% in its stock price over the last five trading days. businesswire.com reported 2025-05-14 that VANCOUVER, British Columbia–(BUSINESS WIRE)—- $ABCL–AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause.
Is It Worth Investing in AbCellera Biologics Inc (NASDAQ: ABCL) Right Now?
Moreover, the 36-month beta value for ABCL is 0.34. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ABCL is 223.95M and currently, short sellers hold a 10.27% of that float. On May 20, 2025, ABCL’s average trading volume was 4.38M shares.
ABCL’s Market Performance
ABCL’s stock has seen a -2.86% decrease for the week, with a -16.73% drop in the past month and a -41.21% fall in the past quarter. The volatility ratio for the week is 6.01%, and the volatility levels for the past 30 days are at 6.08% for AbCellera Biologics Inc. The simple moving average for the past 20 days is -9.21% for ABCL’s stock, with a -23.94% simple moving average for the past 200 days.
Analysts’ Opinion of ABCL
The Benchmark Company, on the other hand, stated in their research note that they expect to see ABCL reach a price target of $9. The rating they have provided for ABCL stocks is “Buy” according to the report published on February 22nd, 2024.
KeyBanc Capital Markets gave a rating of “Overweight” to ABCL, setting the target price at $6 in the report published on December 05th of the previous year.
ABCL Trading at -11.10% from the 50-Day Moving Average
After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.99% of loss for the given period.
Volatility was left at 6.08%, however, over the last 30 days, the volatility rate increased by 6.01%, as shares sank -19.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.24% lower at present.
During the last 5 trading sessions, ABCL fell by -3.87%, which changed the moving average for the period of 200-days by -33.81% in comparison to the 20-day moving average, which settled at $2.25. In addition, AbCellera Biologics Inc saw -30.38% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ABCL
Current profitability levels for the company are sitting at:
- -13.95 for the present operating margin
- -3.09 for the gross margin
The net margin for AbCellera Biologics Inc stands at -7.26. The total capital return value is set at -0.64. Equity return is now at value -15.59, with -11.96 for asset returns.
Based on AbCellera Biologics Inc (ABCL), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -1.23.
Currently, EBITDA for the company is -204.15 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 22.19. The receivables turnover for the company is 0.58for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.15.
Conclusion
To wrap up, the performance of AbCellera Biologics Inc (ABCL) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
